Who Paid My Doc
Alina Justiz
Anesthesiology Norman, OK Medical Doctor
NPI 1053405951 CMS profile 319842
1215 Crossroads Blvd Ste 100, Ste 100, Norman, OK 73072
General payments
$5,971
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,040
Through program year 2025, Alina Justiz of Norman, OK is reported in the CMS Open Payments database as having received $5,971 across 146 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,040 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $712 | 11 | |
| 2024 | General | $861 | 20 | |
| 2023 | General | $173 | 6 | |
| 2022 | General | $327 | 8 | |
| 2021 | General | $652 | 19 | |
| 2020 | General | $2,141 | 51 | |
| 2019 | General | $1,103 | 31 |
Beside peers
- Alina Justiz
- Anesthesiology median
- Middle half of Anesthesiology
- National median
In program year 2025, general payments to Alina Justiz were reported at $712. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.
Show as a table
| Year | Alina Justiz | Anesthesiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,103 | $72 | $23–$151 | $163 |
| 2020 | $2,141 | $36 | $17–$120 | $114 |
| 2021 | $652 | $49 | $21–$135 | $132 |
| 2022 | $327 | $52 | $22–$144 | $149 |
| 2023 | $173 | $53 | $23–$143 | $160 |
| 2024 | $861 | $55 | $25–$150 | $164 |
| 2025 | $712 | $58 | $26–$153 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 34 drugsPart D claims
7,843
Drug cost
$258,670
Branded share of claims
47.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 2,473 | $81,947 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 1,015 | $39,025 | |
| Belbuca Buprenorphine Hcl | Brand | 36 | $27,533 | |
| Buprenorphine | Generic | 66 | $17,561 | |
| Naloxone Hcl | Generic | 259 | $16,242 | |
| Oxycodone Hcl | Generic | 520 | $8,400 | |
| Movantik Naloxegol Oxalate | Brand | 21 | $8,063 | |
| Lidocaine | Generic | 111 | $7,965 | |
| Pregabalin | Generic | 265 | $6,487 | |
| Belsomra Suvorexant | Brand | 14 | $6,246 |
The 10 drugs with the highest cost, of 34 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 35 billing codesPaid by Medicare
$55,888
Medicare patients
156
Services billed
2,563
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 42% | |
| Diabetes | 40% | |
| Ischemic heart disease | 35% | |
| Chronic kidney disease | 32% | |
| COPD | 31% | |
| Heart failure | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 112 | 1,980 | $174 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 31 | 116 | $33 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
146 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Anesthesiology in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Anesthesiology
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.